Active substance
Gliclazide
- SFDA 17
- Health Canada 16
- NHS prices 5
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CLAZ MR 30 mg tablet | 30 mg | modified-release tablet · Oral use | 30 Blister | SAR 21.60 | Generic · Prescription | APOTEX INC. (SIGNET SITE) | Valid |
| CLAZ MR 60 mg tablet | 60 mg | modified-release tablet · Oral use | 30 Blister | SAR 21.60 | Generic · Prescription | APOTEX INC. (SIGNET SITE) | Valid |
| DIAMICRON 60MG MR TABLET | 60 mg | modified-release tablet · Oral use | 30 Blister | SAR 24.00 | NCE · Prescription | SERVIER | Valid |
| DIAMICRON MR TABLET | 30 mg | modified-release tablet · Oral use | 30 Blister | SAR 24.00 | NCE · Prescription | SERVIER | Valid |
| DIAOPTIM MR | 60 mg | modified-release tablet · Oral use | 30 Blister | SAR 24.00 | Generic · Prescription | AJA PHARMACEUTICAL INDUSTRIES | Valid |
| GLAZE 80MG TAB | 80 mg | Tablet · Oral use | 60 Blister | SAR 34.95 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| GLAZE 80MG TAB | 80 mg | Tablet · Oral use | 20 Blister | SAR 13.25 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Glyvanza | 60 mg | modified-release tablet · Oral use | 30 Blister | SAR 21.60 | Generic · Prescription | SAUDI PHARMACEUTICAL INDUSTRIES | Valid |
| Glyvanza | 30 mg | modified-release tablet · Oral use | 30 Blister | SAR 21.60 | Generic · Prescription | SAUDI PHARMACEUTICAL INDUSTRIES | Valid |
| Zyglic MR | 60 mg | modified-release tablet · Oral use | 30 Blister | SAR 20.40 | Generic · Prescription | Zydus Lifesciences Limited | Valid |
| Zyglic MR | 30 mg | modified-release tablet · Oral use | 30 Blister | SAR 20.40 | Generic · Prescription | Zydus Lifesciences Limited | Valid |
| CLAZ MR 30 mg tablet | 30 mg | modified-release tablet · Oral use | 30 Blister | SAR 21.75 | Generic · Prescription | APOTEX | Withdrawn by MAH · Not Marketed |
| DEBACRON 80MG TABLETS | 80 mg | Tablet · Oral use | 30 Blister | SAR 16.95 | Generic · Prescription | Pharma International Co. | Withdrawn by MAH · Not Marketed |
| DIAMICRON TAB 80MG | 80 mg | Tablet · Oral use | 60 Blister | SAR 41.80 | NCE · Prescription | SERVIER | Withdrawn by MAH · Not Marketed |
| DIAMICRON TAB 80MG | 80 mg | Tablet · Oral use | 20 Blister | SAR 15.85 | NCE · Prescription | SERVIER | Withdrawn by MAH · Not Marketed |
| GLIZIDE 80MG TAB | 80 mg | Tablet · Oral use | 30 Blister | SAR 17.90 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| GLUCOZIDE 80MG TABLETS | 80 mg | Tablet · Oral use | 60 Tablet Container | SAR 31.45 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
DIABETES MELLITUS TYPE 2
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AG-GLICLAZIDE MR | 02483300 | 30 MG | TABLET (EXTENDED-RELEASE) · ORAL | ANGITA PHARMA INC. |
| AG-GLICLAZIDE MR | 02483319 | 60 MG | TABLET (EXTENDED-RELEASE) · ORAL | ANGITA PHARMA INC. |
| APO-GLICLAZIDE | 02245247 | 80 MG | TABLET · ORAL | APOTEX INC |
| APO-GLICLAZIDE MR | 02297795 | 30 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| APO-GLICLAZIDE MR | 02407124 | 60 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| DIAMICRON MR | 02242987 | 30 MG | TABLET (EXTENDED-RELEASE) · ORAL | SERVIER CANADA INC |
| DIAMICRON MR | 02356422 | 60 MG | TABLET (EXTENDED-RELEASE) · ORAL | SERVIER CANADA INC |
| GLICLAZIDE | 02287072 | 80 MG | TABLET · ORAL | SANIS HEALTH INC |
| JAMP GLICLAZIDE-MR | 02429764 | 30 MG | TABLET (EXTENDED-RELEASE) · ORAL | JAMP PHARMA CORPORATION |
| JAMP GLICLAZIDE-MR | 02429772 | 60 MG | TABLET (EXTENDED-RELEASE) · ORAL | JAMP PHARMA CORPORATION |
| MINT-GLICLAZIDE MR | 02423286 | 30 MG | TABLET (EXTENDED-RELEASE) · ORAL | MINT PHARMACEUTICALS INC |
| MINT-GLICLAZIDE MR | 02423294 | 60 MG | TABLET (EXTENDED-RELEASE) · ORAL | MINT PHARMACEUTICALS INC |
| MYLAN-GLICLAZIDE MR | 02438658 | 30 MG | TABLET (EXTENDED-RELEASE) · ORAL | MYLAN PHARMACEUTICALS ULC |
| TARO-GLICLAZIDE MR | 02439328 | 60 MG | TABLET (EXTENDED-RELEASE) · ORAL | SUN PHARMA CANADA INC |
| TARO-GLICLAZIDE MR | 02463571 | 30 MG | TABLET (EXTENDED-RELEASE) · ORAL | SUN PHARMA CANADA INC |
| TEVA-GLICLAZIDE | 02238103 | 80 MG | TABLET · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Gliclazide 160mg tablets | £3.27 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Gliclazide 30mg modified-release tablets | £1.08 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Gliclazide 40mg tablets | £0.99 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Gliclazide 60mg modified-release tablets | £7.85 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Gliclazide 80mg tablets | £0.82 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 18.5.2. Hypoglycaemic agents · core
Type 2 diabetes mellitus
Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.